Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Colorcon
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson

Last Updated: September 27, 2022

Details for Patent: 7,855,217


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 7,855,217
Title:Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Abstract:Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Inventor(s): Jaworsky; Markian S. (Hopewell, NJ), Chen; Roger Shen-Chu (Edison, NJ), Muller; George W. (Bridgewater, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:12/335,395
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,855,217
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Drugs Protected by US Patent 7,855,217

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-005 Dec 21, 2011 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-001 Dec 27, 2005 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-002 Dec 27, 2005 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-003 Jun 29, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-006 Jun 5, 2013 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-004 Jun 29, 2006 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,855,217

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2324 See Plans and Pricing
Argentina 047994 See Plans and Pricing
Argentina 057868 See Plans and Pricing
Argentina 102756 See Plans and Pricing
Austria 459357 See Plans and Pricing
Austria 531369 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Mallinckrodt
Boehringer Ingelheim
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.